Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external cont ...

AMT-130 was generally well-tolerated, with a manageable safety profile at both doses. As of June 30, 2025, no new drug-related serious adverse events have been observed since December 2022. The most ...

Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM ...

Migraine is a spectrum disorder with many manifestations. Understand the official classifications of migraine types, including hemiplegic migraine and retinal migraine, to better manage your condition ...

Though automation reduces the number of jobs in the auto industry, there are still plenty of human workers needed to oversee ...

The Dearborn automaker on Monday told employees that its new product development center in Dearborn will be the new world ...

Laurence is an avid writer, gamer, and traveller with several years of journalistic writing experience under his belt. Having helped create a student-focused magazine at university, he is keen to ...

The Visa Presale Draw entry period will open at 11:00 ET (17:00 CET) on Wednesday, 10 September, and close at 11:00 ET (17:00 CET) on Friday, 19 September. Entry period opens Wednesday, 10 September ...

Keir Starmer has described his shake-up in Downing Street as the "second phase" of his government, insisting it is not a "reshuffle". In a radio interview with the BBC's Matt Chorley, the prime ...

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 - - Zilebesiran Demonstrated Clinically Meaningful ...

– Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – In the Phase II KARDIA-3 study, presented today as a late ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) ...